Detalhe da pesquisa
1.
NSAIDs do not reduce severity among post-ERCP pancreatitis patients.
Pancreatology
; 24(1): 14-23, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-37981523
2.
The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial.
Invest New Drugs
; 39(3): 829-835, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33415580
3.
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract.
Gynecol Oncol
; 158(3): 570-575, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32534809
4.
Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint Inhibitors.
J Immunother Precis Oncol
; 6(2): 91-102, 2023 May.
Artigo
Inglês
| MEDLINE | ID: mdl-37214204
5.
A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma.
Cancers (Basel)
; 15(15)2023 Jul 27.
Artigo
Inglês
| MEDLINE | ID: mdl-37568622
6.
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial.
J Immunother Cancer
; 10(5)2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35618285
7.
Hypercalcemia of Malignancy and Acute Pancreatitis.
Pancreas
; 50(2): 206-213, 2021 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33565797